📌WARREN BUFFETT'S INVESTING RULES: WHEN TO BUY, HOLD AND SELL
A disciplined investor doesn't react emotionally to every market move. They follow a strategy.
When a stock falls:
1. Down 5% → Do nothing.
2. Down 15% → Increase your position by 10%.
3. Down 25% → Increase your position by 25%.
When a stock rises:
4. Up 5% → Hold.
5. Up 15% → Continue holding.
6. Up 25% → Sell 10% of your position.
7. Up 35% → Sell 20%.
8. Up 45% → Sell 30%.
9. Up 60% → Sell 40%.
10. Up 100% → Exit the entire position.
The real secret to investing isn't predicting every market move. It's having a clear strategy before the market moves
Know when to buy, when to hold and when to take profits.
Discipline beats emotion. Strategy beats impulse
If you find my post helpful, please like, follow and share
2015 — You missed NVIDIA.
2016 — You missed Tesla.
2017 — You missed Bitcoin’s breakout.
2018 — You missed Amazon.
2019 — You missed Microsoft.
2020 — You missed Apple.
2021 — You missed Tesla’s second run.
2022 — You missed NVIDIA’s AI ignition.
2023 — You missed Super Micro.
2024 — You missed Broadcom.
2025 — You missed Palantir.
2026 — What are you still missing?
Three Fundamental Principles of Investing
1. Invest only money that you can afford to lose without affecting your daily life—ideally no more than 30% of your total assets.
2. Once you have made an investment, stop dwelling on it; trust your own judgment.
3. Invest in companies whose products have future growth potential, rather than those in declining industries.
Notice:
Investments 10 years ago that are now worth $1M:
$TSLA Tesla: $37,000
$SHOP Shopify: $25,300
$MU Micron: $19,500
$AMD : $12,800
$NVDA Nvidia: $7,800
Investments in 2026 that could be worth $1M in 10 years:
1. Broadcom ( $AVGO )
Custom AI chips (ASICs) + high-speed networking chips. One of the most direct ways to play AI data center capital spending outside of Nvidia.
2. Taiwan Semiconductor ( $TSM )
The world’s leading advanced-process foundry. Almost every top-tier AI chip (Nvidia, AMD, Apple, etc.) is manufactured by TSMC. One of the most solid “picks and shovels” plays in the AI supply chain.
3. Rocket Lab ( $RKLB )
Small-launch rockets + satellite manufacturing and systems. One of the few pure-play commercial space companies that already has meaningful revenue and a real backlog. Narrative similar to an earlier-stage space supply chain player.
4. Palantir ( $PLTR )
Enterprise AI software platform. Already deploying AI into real government and large-enterprise workflows. One of the more commercially advanced names in the AI application layer.
5. Micron Technology ( $MU )
Key supplier of high-bandwidth memory (HBM). AI servers have driven a sharp surge in demand for advanced memory, making Micron another critical piece of the AI hardware stack.
I've consistently outperformed the markets, making generational-wealth trades you don't want to miss.
Many will regret not following me for more.
If you find this information helpful, please like, follow and share
THE NUMBERS SPEAK FOR THEMSELVES
For reference, I've previously advocated:
- $TSLA: $46.7 → Soared +1,080% (10.8x)
- $NVDA: $15.8 → Soared +1,540% (15.4x)
- $MU: $83.7 → Soared +1,499% (15x)
- $AAPL: $61.8 → Soared +563% (5.6x)
- $WMT: $46.9 → Soared +288% (3.9x)
- $NBIS: $20 → Soared +1,399% (14x)
- $RKLB: $16 → Soared +844% (8.4x)
- $AMD: $100 → Soared +505% (6x)
- $ASTS: $20 → Soared +569% (5.7x)
- $PLTR: $40 → Soared +419% (5.2x)
I focus on uncovering overlooked companies, the next big opportunity may be closer than you think.
If you find my post helpful, please like, follow , share
I've consistently outperformed the markets, making generational-wealth trades you don't want to miss.
Many will regret not following me for more.
I'm 55, retired from Vanguard Group , have spent decades studying the markets. Here's my advice for November 13:
1. $NVDA — The bad news is out. It's time to buy
$NVDA — BUY at $155–$160. The bad news has been fully priced in. It's time to buy.
$AMD — Strong AI growth, but don't chase after the recent rally.
$TSLA — Huge long-term potential, but valuation remains a concern. Don't buy for now.
$AVGO — Buy at $330–$340
$QCOM — Buy at $164–$170
$MRVL — Buy at $153–$157
$ANET — Buy at $190–$196
$TSM — Buy at $392–$403
$MU — Don't chase after the recent rally
If you find this information helpful, please like, follow, share
1. NVIDIA ( $NVDA ): 16% of the portfolio
2. Alphabet ( $GOOGL ): 13% of the portfolio
3. Broadcom ( $AVGO ): 12% of the portfolio
4. Bloom Energy ( $BE ): 10% of the portfolio
5. Palo Alto Networks ( $PANW ): 8% of the portfolio
If you find this information helpful, please like, follow, and share
Oh my god, she bought so much again!
Nancy Pelosi has 85% of her portfolio in just 5 stocks.
This is how the House Democrat is invested right now:
1) $NVDA – 16.0% of portfolio
Here's the breakdown:
1. Palantir ($PLTR) — 65.0%
2. NVIDIA ($NVDA) — 13.5%
3. Pfizer ($PFE) — 11.1%
4. Halliburton ($HAL) — 4.5%
Palantir and NVIDIA together account for 78.5% of the total share capital
That's a serious concentration of conviction.
Which position stands out to you?
If you found it useful, follow @EasonBrooksQ for more daily
If you are under 60, I’m only going to say this ONCE.
79% OF MICHAEL BURRY'S PORTFOLIO. JUST TWO STOCKS.
That's how heavily one of Wall Street's most closely watched investors concentrated his publicly disclosed holdings.
Here's the breakdown:
1.NVIDIA ($NVDA) — 13.5%
1. Prime Medicine $PRME : Prime Editing platform. Focus: In vivo gene editing for the treatment of hereditary liver diseases. Market capitalization: $779 million
2. Twist Bioscience $TWST: Synthetic biology/DNA synthesis platform. Large-scale, low-cost DNA synthesis using silicon-based chip technology. Market capitalization: $924 million
3. Natera $NTRA: Non-invasive liquid biopsy/cfDNA testing.
Three main sectors:
• Oncology: Signatera (personalized ctDNA/MRD testing, monitoring relapse and treatment efficacy), Latitude, etc.; Market capitalization: $4.6 billion
4. Scribe Therapeutics $SCTX: In vivo CRISPR gene editing/epigenetic silencing (IPO in July 2026). Focus: Cardiovascular and metabolic diseases. Market capitalization: $320 million
5. Tempus AI $TEM: AI + precision medicine platform. It provides tumor and genetic-related NGS testing, multimodal data integration, AI-driven clinical decision support, clinical trial matching, and drug development data licensing. Market capitalization: $1.45 billion
Common themes:
gene editing, liquid biopsy, synthetic biology, and AI-enabled precision medicine, aligning with ARK Genomic Revolution's (ARKG) long-term investment logic.
If my post was helpful, please like, follow, and share.